Gavin Babbage

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Alasdair Munro, Shuo Feng, Leila Janani et al. · The Lancet Infectious Diseases · 2022 · 177 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study

Nathan J. Brendish, Stephen Poole, Vasanth V Naidu et al. · The Lancet Respiratory Medicine · 2020 · 134 citations · Full text

Veterinary Medicine, Infectious Disease Control, Infectious Diseases +17

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.

Xinxue Liu, Alasdair Munro, Shuo Feng et al. · Journal of Infection · 2022 · 66 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

Xinxue Liu, Alasdair Munro, Annie Wright et al. · Journal of Infection · 2023 · 40 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14